# Henry Schein Inc. (HSIC)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/HSIC/primer

## Business Model

---
source: coverage-next-full
ticker: HSIC
step: "01"
title: Business Overview — Segments, Model, Strategy
created: 2026-05-29
---

### Step 01: Business Overview — Henry Schein, Inc.

#### Company Description

Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental and medical practitioners. Founded in 1932 in Flushing, New York, the company serves approximately 1 million customers worldwide through a combination of physical product distribution, digital commerce, and software-enabled practice management tools.

The company operates a "value-added distribution" model — going beyond simple product logistics to embed software, financial services, and clinical education into customer workflows, creating stickiness well beyond what a commodity distributor enjoys.

#### Business Segments

##### 1. Dental Segment (~75% of Revenue)

The Dental segment provides dental practitioners with consumable products, dental equipment, and technology/software solutions. Key sub-verticals:

**Consumables (~50% of dental revenue)**
- Infection control products (gloves, masks, barriers)
- Impression materials and restorative products
- Anesthetics, cements, and bonding agents
- Lab products and small hand instruments
- Prophylaxis products (prophy paste, polishing cups)

**Equipment (~20% of dental revenue)**
- Dental chairs, delivery systems, lighting
- Digital imaging (x-ray, CBCT scanners, intraoral cameras)
- Sterilization equipment
- CAD/CAM systems (digital dentistry)

**Technology/Software (~30% of dental revenue)**
- **Henry Schein One (HS1)** — umbrella brand for practice management software
  - **Dentrix** — dominant US dental practice management software (300,000+ practitioners)
  - **Eaglesoft** — second major PM platform (acquired from Patterson-era competitor)
  - **Curve Dental** — cloud-native practice management (cloud-first practices)
  - **Lighthouse 360** — patient communication and recall automation
  - **Carestream Dental** (imaging software components)
- Revenue cycle management (RCM) for dental practices
- Patient engagement and teledentistry tools

**Geographic Mix (Dental)**
- North America: ~55% of dental segment
- International: ~45% of dental segment (Europe, Australia, Canada primary markets)

##### 2. Medical Segment (~25% of Revenue)

The Medical segment serves office-based physician practices, community health centers, and ambulatory care facilities. Key products:

- Injectable medications and vaccines
- Wound care products
- Diagnostic supplies (glucose monitoring, diagnostic kits)
- Surgical instruments and PPE
- Rehabilitation products
- AED devices and emergency products

**Key customers**: Primary care physicians, urgent care clinics, community health centers, surgical centers, long-term care facilities.

**Competitive position**: Top-3 distributor to office-based physicians in the US. Competes primarily with McKesson Medical, Cardinal Health, and Medline.

#### Business Model

Henry Schein's distribution model operates on two economic pillars:

1. **Product Distribution**: High-SKU (~300,000+ SKUs), high-touch distribution to fragmented small-practice customers. HSIC differentiates through field sales representatives ("field sales consultants") who call on dental offices, cross-sell products, and provide clinical education. The sales force creates switching friction beyond what a pure e-commerce competitor can replicate.

2. **Software/Technology**: Henry Schein One (HSOne) generates recurring SaaS-like revenue from subscription-based practice management software. This segment enjoys ~80% gross margins vs. ~30% for consumables distribution — the strategic prize driving HSIC's technology investment.

#### Key Operating Statistics (FY2023)

| Metric | Value |
|--------|-------|
| Net Revenue | ~$12.35B |
| Countries Operated | 32+ |
| Customers Served | ~1 million |
| Team Schein Members (employees) | ~24,000 |
| Dental Software Users (Dentrix/Eaglesoft) | ~300,000+ practitioners |
| Field Sales Reps | ~5,000+ |
| SKUs Offered | ~300,000+ |

#### Strategic Priorities

1. **DSO (Dental Service Organization) Penetration**: The US dental market is consolidating around DSOs (multi-location dental chains like Heartland Dental, Aspen Dental, Pacific Dental). HSIC has a dedicated DSO sales team and is the preferred distributor for many of the largest DSOs. DSOs are credit-worthy, large-volume purchasers with lower cost-to-serve.

2. **Henry Schein One Expansion**: Growing HSOne from point-of-sale practice management to a full "dental operating system" — incorporating patient financing, teledentistry, insurance eligibility, and revenue cycle management. HSOne commands a premium ASP and better margin than product distribution.

3. **Specialty Dental Growth**: Orthodontics (clear aligners), implants, and oral surgery are the fastest-growing segments of the dental market. HSIC has been acquiring and investing in specialty distribution and software.

4. **International Expansion**: International dental is ~45% of dental segment revenue. Key markets include Germany, UK, Netherlands, France, Australia. Opportunities in emerging dental markets (Brazil, China through partnerships).

5. **Acquisitions**: HSIC has historically made 5-10 bolt-on acquisitions per year, primarily in dental distribution, dental software, and specialty products. The 2022 acquisition of Shield Healthcare (home health supplies) and various dental software tuck-ins are examples.

#### Corporate Governance Overview

- **Headquarters**: 135 Duryea Road, Melville, New York 11747
- **CEO**: Stanley Bergman (Chairman & CEO since 1989 — over 35 years)
- **CFO**: Ronald South (appointed 2022; previously corporate controller)
- **Listed**: NASDAQ (HSIC)
- **Index Membership**: S&P 500, NASDAQ-100 (removed 2024)
- **Shares Outstanding**: ~135 million diluted (FY2024)

## Financial Snapshot

---
source: coverage-next-full
ticker: HSIC
step: "04"
title: Financial Snapshot — 3-Year P&L, Key Metrics
created: 2026-05-29
---

### Step 04: Financial Snapshot — 3-Year P&L Summary

#### Income Statement Summary

| Metric | FY2021 | FY2022 | FY2023 | 3-Yr CAGR |
|--------|--------|--------|--------|-----------|
| **Net Revenue** | $12,437M | $12,630M | $12,349M | -0.4% |
| **Cost of Sales** | $8,006M | $8,163M | $7,994M | |
| **Gross Profit** | $4,431M | $4,467M | $4,355M | -0.9% |
| **Gross Margin** | 35.6% | 35.4% | 35.3% | |
| **Operating Expenses** (SG&A) | $3,190M | $3,290M | $3,420M | |
| **Restructuring/Cyber Costs** | — | — | ~$50M | |
| **Operating Income (EBIT)** | $1,241M | $1,177M | $885M | -16.2% |
| **EBIT Margin** | 9.98% | 9.32% | 7.17% | |
| **Adj. EBIT (ex-cyber/one-time)** | ~$1,241M | ~$1,177M | ~$1,010M | |
| **Adj. EBIT Margin** | 9.98% | 9.32% | 8.18% | |
| **Net Interest Expense** | $(62)M | $(86)M | $(121)M | |
| **Pre-Tax Income** | $1,179M | $1,091M | $764M | |
| **Income Tax Expense** | $264M | $246M | $191M | |
| **Effective Tax Rate** | 22.4% | 22.5% | 25.0% | |
| **Net Income (GAAP)** | $835M | $734M | $478M | -24.4% |
| **Net Income Margin** | 6.7% | 5.8% | 3.9% | |
| **Adj. Net Income (ex-one-time)** | ~$835M | ~$734M | ~$640M | |
| **Diluted EPS (GAAP)** | $5.79 | $5.24 | $3.51 | |
| **Adj. Diluted EPS** | ~$5.79 | ~$5.58 | ~$4.72 | |
| **Diluted Shares Outstanding** | 144.2M | 140.1M | 136.2M | |

Note: FY2023 GAAP results were heavily impacted by the October 2023 cybersecurity incident. Adjusted figures exclude approximately $150-175M in cyber-related costs (lost revenue impact, recovery expenses, legal/insurance accruals). The effective tax rate was also higher in FY2023 due to unfavorable discrete items.

#### Adjusted EPS Bridge (FY2022 → FY2023)

| Factor | EPS Impact |
|--------|-----------|
| FY2022 Adj. EPS baseline | $5.58 |
| Organic volume/price improvement | +$0.30 |
| Cyber incident (lost revenue + costs) | -$(1.00) |
| Higher interest expense | -$(0.25) |
| Share count reduction (buybacks) | +$0.12 |
| FX headwind | -$(0.03) |
| **FY2023 Adj. EPS** | **~$4.72** |

#### Key Profitability Metrics

| Metric | FY2021 | FY2022 | FY2023 |
|--------|--------|--------|--------|
| Gross Margin | 35.6% | 35.4% | 35.3% |
| EBIT Margin (adj.) | 9.98% | 9.32% | 8.18% |
| EBITDA Margin (adj.) | 11.5% | 10.8% | 9.7% |
| Net Margin (adj.) | 6.7% | 5.8% | 5.2% |
| FCF Margin | ~4.0% | ~3.5% | ~2.5% |

#### EBITDA Build

| Component | FY2021 | FY2022 | FY2023 |
|-----------|--------|--------|--------|
| Operating Income (Adj.) | $1,241M | $1,177M | $1,010M |
| D&A | $185M | $200M | $210M |
| Stock-Based Compensation | $65M | $70M | $75M |
| **Adj. EBITDA** | **~$1,491M** | **~$1,447M** | **~$1,295M** |
| **Adj. EBITDA Margin** | **12.0%** | **11.5%** | **10.5%** |

#### Revenue Growth Components

| Year | Total Growth | Price/Mix | Volume | FX | M&A |
|------|-------------|-----------|--------|-----|-----|
| FY2021 | +18.5% | +3% | +12% | +1% | +2.5% |
| FY2022 | +1.5% | +2% | +1% | -2% | +0.5% |
| FY2023 | -2.2% | +1% | -3% | -1% | +0.8% |

#### Segment Profitability (Est.)

| Segment | Revenue | Operating Income | Operating Margin |
|---------|---------|-----------------|-----------------|
| Dental (FY2023) | ~$9.1B | ~$850M | ~9.3% |
| Medical (FY2023) | ~$3.1B | ~$250M | ~8.1% |
| Corporate | — | ~$(90M) | — |
| **Total (Adj.)** | **~$12.35B** | **~$1,010M** | **~8.2%** |

Note: Dental segment carries the software/technology sub-segment which has margins of 25-30%+ and disproportionately supports the blended dental margin.

#### Margins vs. Peers

| Company | Gross Margin | EBIT Margin | Context |
|---------|-------------|-------------|---------|
| **HSIC** | 35.3% | 8.2% (adj.) | Value-added dental dist. + software |
| Patterson (PDCO) | 28.0% | 6.0% | Dental + animal health distributor |
| McKesson (MCK) | 5.0% | 2.5% | Drug distributor (lower margin by nature) |
| Cardinal Health (CAH) | 3.8% | 1.8% | Drug distributor |
| AmerisourceBergen (ABC) | 3.5% | 1.7% | Drug distributor |

HSIC's gross margin premium (35% vs. 28% for PDCO, >30% vs. drug distributors) reflects:
1. Higher-value dental products (materials vs. pills)
2. Software revenue mix (~15% of revenue at 70%+ gross margins)
3. Value-added services bundled into pricing

#### Working Capital Dynamics

| Metric | FY2022 | FY2023 |
|--------|--------|--------|
| Days Sales Outstanding (DSO) | ~42 days | ~44 days |
| Days Inventory Outstanding (DIO) | ~38 days | ~40 days |
| Days Payable Outstanding (DPO) | ~48 days | ~50 days |
| Cash Conversion Cycle (CCC) | ~32 days | ~34 days |

HSIC's cash conversion cycle is modest for a distributor, though the cyber incident slightly elevated DSO as customers took longer to pay during the disruption period.

#### Forward Estimates (FY2024E)

| Metric | FY2024E (Consensus) |
|--------|---------------------|
| Revenue | ~$12.8B |
| Adj. EBIT | ~$830M-860M |
| Adj. EBIT Margin | ~6.5-6.7% |
| Adj. EPS | ~$4.60-4.90 |
| Adj. EBITDA | ~$1,050-1,080M |

Note: FY2024 consensus assumes continued cyber recovery, some normalization of legal/insurance costs related to cyber, and gradual HSOne subscription growth. The margin outlook is weaker than FY2022 as the company invests in technology/DSO sales infrastructure.

## Recent Catalysts

---
source: coverage-next-full
ticker: HSIC
step: "12"
title: Catalysts — Near-Term Events and Bull/Bear Framework
created: 2026-05-29
---

### Step 12: Catalysts

#### Near-Term Catalysts (Next 12-18 Months)

##### Catalyst 1: Resolution of Cyber Legal Matters
**Timeline**: Q2 2025 – Q4 2026
**What to watch**: Class action lawsuit settlements, HHS/OCR resolution, state AG outcomes
**Bull case outcome**: HSIC settles all cyber-related litigation and regulatory matters within existing insurance coverage (~$150M); total above-insurance out-of-pocket cost <$50M. Removes the "unknown liability" overhang that has suppressed the valuation multiple.
**Bear case outcome**: HHS levies major HIPAA penalties; class action settles for $200M+ above insurance coverage; ongoing legal costs drag EPS by $0.50+ through 2027.
**Probability of bull outcome**: 55% (insurance coverage appears adequate for base case)
**EPS impact**: +$0.40-0.60 if resolved favorably (multiple expansion + cost removal)

##### Catalyst 2: Q4 2024 / FY2024 Earnings (Easy Cyber Comp)
**Timeline**: Q1 2025 earnings release
**What to watch**: Q4 2024 dental revenue vs. Q4 2023 devastated comp; recovery in DSO customer relationships
**Expected outcome**: Q4 2024 organic dental growth of 8-12% (vs. -24.8% in Q4 2023); dramatic GAAP EPS recovery
**Risk**: If Q4 2024 comes in below the easy comp (organic < 7%), it suggests permanent customer loss is worse than expected
**Catalyst significance**: Medium — widely anticipated, largely priced in; magnitude matters

##### Catalyst 3: Henry Schein One (HSOne) ARR Disclosure
**Timeline**: FY2024 investor day or Q4 earnings
**What to watch**: First detailed HSOne ARR disclosure (management has been somewhat opaque about HSOne financials)
**Bull case**: HSIC separately reports HSOne ARR of $700M+, growing 12-15%; commands a 20-25x ARR multiple (implies $14-17.5B valuation for software alone — vs. HSIC's entire ~$9B market cap)
**Bear case**: HSOne growth below 10%, churn rising due to Fuse/cloud competition; management avoids specific disclosure
**Probability**: Management was reportedly considering an HSOne investor day as of 2024; any concrete ARR disclosure would be significant

##### Catalyst 4: DSO Strategic Announcements / Contract Wins
**Timeline**: Rolling, any quarter
**What to watch**: Multi-year preferred supplier agreements with top-20 DSOs; HSOne enterprise deals
**Magnitude**: A single contract with Heartland Dental (1,700 locations) for HSOne across all locations could add ~$10-15M incremental ARR
**Why it matters**: Institutional investors are watching whether DSO adoption of HSOne validates the software strategy

##### Catalyst 5: Strategic Review / HSOne Separation
**Timeline**: 2-3 year horizon (medium-term)
**What to watch**: Activist pressure or board-initiated review of separating HSOne from the distribution business
**Precedent**: McKesson spun off Change Healthcare; Cardinal separated specialty pharma businesses
**Value case**: A standalone HSOne business at SaaS multiples (~20-25x EBITDA) vs. the current blended distribution multiple (~11-12x) would create significant value
**Probability**: 15-20% within 3 years; activist interest in HSIC has been rumored
**Potential share price impact**: +$20-35/share if separation announced

##### Catalyst 6: Acquisition of Specialty Dental Asset
**Timeline**: 12-24 months
**What to watch**: A major specialty dental acquisition (implants, orthodontics, or digital workflow platform)
**Historical precedent**: Hu-Friedy ($425M, 2019) added high-margin premium instruments; strategic dental software acquisitions add HSOne capability
**Positive scenario**: HSIC acquires a high-growth specialty dental software company (e.g., an orthodontic workflow platform) at reasonable multiples, accelerating HSOne's specialty penetration
**Negative scenario**: HSIC overpays for an acquisition at a peak valuation, destroying capital

##### Catalyst 7: Macro Dental Volume Recovery
**Timeline**: FY2025-2026
**What to watch**: ADA dental utilization surveys; practice revenue data from dental group practice consolidators (Henry Schein One has visibility)
**Bull trigger**: Post-pandemic catch-up demand (deferred implants, orthodontics) + dental benefits expansion drives 5-6% market growth → dental segment organic revenue growth 6-8%
**Bear trigger**: US recession → elective procedure deferrals → dental market contracts 2-3%

---

#### Bull Case

**Bull Case**
- Cyber legal resolution removes the ~$50-75M annual cost overhang and the valuation multiple discount, driving EPS recovery to $6.00+ by FY2026 while an HSOne ARR disclosure unlocks a re-rating from 12x to 16x earnings
- Henry Schein One's 300,000+ practitioner installed base and 2-3% churn rate represents a growing, high-ROIC software annuity that the market is materially undervaluing at the current blended distribution multiple, with ARR growth accelerating as HSOne expands into RCM, patient financing, and DSO enterprise software
- DSO consolidation (now ~40% of US dental) accelerates HSIC's position as the preferred enterprise dental partner — providing scale-driven volume growth, higher HSOne attach rates, and a structural competitive moat that smaller rivals cannot replicate

#### Bear Case

- Ongoing cyber-related legal liability (HIPAA penalties, class actions) exceeds insurance coverage and drags EPS materially below consensus for 3+ years while permanently damaging customer trust and accelerating defection to Patterson and online channels
- Patterson's Fuse cloud-native practice management software erodes Dentrix/Eaglesoft's installed base meaningfully over 3-5 years, compressing HSOne's premium growth narrative and forcing HSIC to accept lower subscription pricing to defend customer retention
- DSO consolidation creates concentrated pricing pressure on HSIC's core consumables and equipment business, structurally compressing gross margins from 35% to 33-34% over the next 5 years while the distribution competitive moat erodes as manufacturers increasingly sell equipment direct to large DSO groups

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/hsic
- Full research API: GET /api/v1/research/HSIC/memo
- Coverage universe: /stocks